Comparative Pharmacology
Head-to-head clinical analysis: AMINOPHYLLIN versus ELIXOPHYLLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOPHYLLIN versus ELIXOPHYLLIN.
AMINOPHYLLIN vs ELIXOPHYLLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective phosphodiesterase inhibitor, increasing intracellular cAMP and cGMP; adenosine receptor antagonist, causing bronchodilation, CNS stimulation, and positive chronotropic/inotropic effects.
Inhibits phosphodiesterase, increasing intracellular cAMP, leading to bronchodilation and anti-inflammatory effects.
Loading dose: 6 mg/kg IV over 30 minutes (if not on theophylline); maintenance: 0.5-0.7 mg/kg/hr IV continuous infusion for adults (non-smoking), higher for smokers (0.7-0.9 mg/kg/hr). Oral: immediate-release 200-400 mg every 6 hours; sustained-release 400-600 mg every 12 hours.
Theophylline (Elixophyllin) immediate-release: Initial dose 300 mg/day PO divided every 6-8 hours; titrate based on serum theophylline concentration (target 5-15 mcg/mL). Typical adult dose 400-600 mg/day PO divided every 6-8 hours. Sustained-release: 400-600 mg/day PO every 12 hours.
None Documented
None Documented
Clinical Note
moderateAminophylline + Gatifloxacin
"The metabolism of Gatifloxacin can be decreased when combined with Aminophylline."
Clinical Note
moderateAminophylline + Rosoxacin
"The metabolism of Rosoxacin can be decreased when combined with Aminophylline."
Clinical Note
moderateAminophylline + Levofloxacin
"The metabolism of Levofloxacin can be decreased when combined with Aminophylline."
Clinical Note
moderateAminophylline + Trovafloxacin
Terminal elimination half-life: 3–12 hours in adults (mean ~6 hours); prolonged in hepatic impairment, heart failure, or COPD (up to 30 hours); shorter in smokers (4–5 hours due to CYP1A2 induction); neonates: 20–40 hours.
Terminal elimination half-life in adults is approximately 7-9 hours (range 3-12 hours) for non-smokers, and 4-5 hours for smokers. In children (1-9 years), half-life averages 3-4 hours; in neonates, it is prolonged (20-30 hours). Clinical context: Half-life may be increased in hepatic impairment, congestive heart failure, and with concurrent administration of drugs that inhibit CYP1A2 and CYP3A4 (e.g., cimetidine, erythromycin, ciprofloxacin). Decreased half-life occurs with enzyme inducers (e.g., phenytoin, carbamazepine, rifampin, smoking).
Renal excretion of unchanged drug accounts for ~10%, with the remainder eliminated as metabolites (caffeine, 3-methylxanthine, 1-methyluric acid, 1,3-dimethyluric acid) via urine; minimal biliary/fecal elimination (<5%).
Theophylline is primarily eliminated by hepatic metabolism (approximately 90%), with less than 10% excreted unchanged in urine. Renal excretion of unchanged drug accounts for about 10% in adults, but in neonates and infants, it may be higher (up to 50%). Fecal excretion is negligible (<1%).
Category C
Category C
Xanthine Bronchodilator
Xanthine Bronchodilator
"The metabolism of Trovafloxacin can be decreased when combined with Aminophylline."